Compare KITT & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KITT | PFSA |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | KITT | PFSA |
|---|---|---|
| Price | $0.90 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1M | ★ 54.5M |
| Earning Date | 11-14-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,840.00 | N/A |
| Revenue This Year | $2,936.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 95.38 | ★ 122.22 |
| 52 Week Low | $0.69 | $0.07 |
| 52 Week High | $54.36 | $12.76 |
| Indicator | KITT | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | N/A |
| Support Level | $0.69 | N/A |
| Resistance Level | $1.10 | N/A |
| Average True Range (ATR) | 0.10 | 0.00 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 50.94 | 0.00 |
Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.